Please login to the form below

Not currently logged in
Email:
Password:

Acorda appoints new CFO

Michael Rodgers replaces David Lawrence who becomes chief business officer

Acorda has reshuffled its senior business leadership, with Michael Rodgers appointed chief financial officer replacing David Lawrence who becomes chief business officer.

Rodgers joins from BG Medicine where he also served as chief financial officer. During his time at BG he led the company's initial public offering and helped launch its first product.

His previous roles include chief financial officer of Indevus Pharmaceuticals, where he stayed for 10 years before the company was acquired by Endo Pharmaceuticals.

Rodgers' predecessor as Acorda's chief financial officer David Lawrence moves to the newly-created role of chief business officer, where he will be responsible for the company's technical operations, project management, IT and facilities.

“We've grown rapidly over the past several years, and our internal operations need to keep pace with the demands of the business,” said Lawrence.

“I'm excited to take on this new challenge at Acorda, overseeing and optimising development of our business operations and infrastructure.”

This growth is led by six therapies in clinical studies that address a range of disorders including post-stroke deficits, epilepsy, cerebral palsy, stroke, peripheral nerve damage, spinal cord injury, neuropathic pain and heart failure. 

9th October 2013

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
certain health

Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....